Nora Therapeutics Company

Nora Therapeutics is a specialty biopharmaceutical company developing therapeutics to address clinical unmet needs in reproductive medicine. Nora’s lead compound, NT100, is a novel treatment being studied to improve pregnancy success rates and outcomes for women who have undergone multiple unsuccessful in vitro fertilization (IVF) procedures. NT100 is a novel biologic agent similar to a naturally occurring protein in the female reproductive tract. NT100’s mechanism of action may better enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance.
Technology: Longevity FemTech
Industry: Biotechnology, Health Care, Medical Device
Headquarters: Palo Alto California, United States
Founded Date: 6-29
Employees Number: 11-50
Funding Status: Early Stage Venture
Investors Number: 5
Total Funding: $36.8M
Estimated Revenue: $1M to $10M
Last Funding Type: Series B

Visit Website
info@noratherapeutics.com
Register and Claim Ownership